Structural features of heparin and its interactions with cellular prion protein measured by surface plasmon resonance
Author
Kim, So Young; Zhang, Fuming; Harris, David A.; Linhardt, Robert J.
Other Contributors
Date Issued
2020-11-26Subject
Biology; Chemistry and chemical biology; Chemical and biological engineering; Biomedical engineeringDegree
Terms of Use
CC BY : this license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. Credit must be given to the authors and the original work must be properly cited.; Attribution 3.0 United StatesFull Citation
Structural features of heparin and its interactions with cellular prion protein measured by surface plasmon resonance, S. Y. Kim, F. Zhang, D. A. Harris, R. J. Linhardt, Frontiers in Molecular Biosciences 7, 594497, 2020.Metadata
Show full item recordAbstract
Self-propagating form of the prion protein (PrPSc) causes many neurodegenerative diseases, such as Creutzfeldt-Jakob disease (CJD) and Gerstmann-Straussler-Scheinker syndrome (GSS). Heparin is a highly sulfated linear glycosaminoglycan (GAG) and is composed of alternating D-glucosamine and L-iduronic acid or D-glucuronic acid sugar residues. The interactions of heparin with various proteins in a domain-specific or charged-dependent manner provide key roles on many physiological and pathological processes. While GAG-PrP interactions had been previously reported, the specific glycan structures that facilitate interactions with different regions of PrP and their binding kinetics have not been systematically investigated. In this study, we performed direct binding surface plasmon resonance (SPR) assay to characterize the kinetics of heparin binding to four recombinant murine PrP constructs including full length (M23–230), a deletion mutant lacking the four histidine-containing octapeptide repeats (M23–230 Δ59–90), the isolated N-terminal domain (M23–109), and the isolated C-terminal domain (M90–230). Additionally, we found the specific structural determinants required for GAG binding to the four PrP constructs with chemically defined derivatives of heparin and other GAGs by an SPR competition assay. Our findings may be instrumental in developing designer GAGs for specific targets within the PrP to fine-tune biological and pathophysiological activities of PrP.;Description
Frontiers in Molecular Biosciences 7, 594497; Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.Department
The Linhardt Research Labs.; The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS);Publisher
Frontiers Media SARelationships
The Linhardt Research Labs Online Collection; Rensselaer Polytechnic Institute, Troy, NY; Frontiers in Molecular Biosciences; https://harc.rpi.edu/;Access
CC BY — Creative Commons Attribution; Open Access; A full text version is available in DSpace@RPI;Collections
The following license files are associated with this item: